ID   ZEC-166
AC   CVCL_VT88
DR   CCRID; 4201PAT-CCTCC00888
DR   Wikidata; Q98136474
RX   Patent=CN106190982A;
CC   Group: Patented cell line.
CC   Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C201687.
CC   Population: Chinese.
CC   Doubling time: ~85 hours (Patent=CN106190982A).
CC   Derived from site: In situ; Esophagus; UBERON=UBERON_0001043.
ST   Source(s): Patent=CN106190982A
ST   Amelogenin: X
ST   CSF1PO: 10,11
ST   D12S391: 23
ST   D13S317: 9
ST   D16S539: 11,12
ST   D18S51: 16,19
ST   D19S433: 14
ST   D21S11: 29
ST   D2S1338: 20,24
ST   D3S1358: 15
ST   D5S818: 10,11
ST   D6S1043: 11,13,14
ST   D7S820: 10
ST   D8S1179: 10,11
ST   FGA: 22
ST   Penta D: 11
ST   Penta E: 10,12
ST   TH01: 6,9
ST   TPOX: 9
ST   vWA: 18
DI   NCIt; C4024; Esophageal squamous cell carcinoma
DI   ORDO; Orphanet_99977; Squamous cell carcinoma of the esophagus
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   67Y
CA   Cancer cell line
DT   Created: 24-05-19; Last updated: 29-06-23; Version: 9
//
RX   Patent=CN106190982A;
RA   Su D., Xiong L., Mao W.-M., Zhao Q., Ying L.-S., Xie Z.-H., Wu J.-Z.;
RT   "Esophagus cancer cell line and application thereof.";
RL   Patent number CN106190982A, 07-Dec-2016.
//